Xeris Biopharma Stock Soars 12.02% on Record Q2 Earnings

Xeris Biopharma's stock surged 12.02% in pre-market trading on August 7, 2025, driven by the company's impressive financial performance and strategic initiatives.

Xeris Biopharma reported record financial results for the second quarter of 2025, with total revenue increasing by 49% year-over-year to $71.5 million. This growth was primarily driven by a 136% increase in Recorlev® revenue, reflecting a significant rise in patient demand. The company also raised its full-year 2025 total revenue guidance to $280-$290 million, up from the previous range of $260-$275 million.

During the quarter, Xeris Biopharma hosted its first-ever Analyst and Investor Day, where it outlined a long-term vision and growth strategy. The company guided to $750 million in total revenue by 2030, with expectations for Recorlev® to reach nearly $1 billion in net revenue by 2035. Additionally, the potential peak net revenue for XP-8121 was highlighted at $1-$3 billion, underscoring the company's accelerated growth trajectory and commitment to value creation.